“…The evolution of devices in serious cardiac rhythm pathology management has led progressively to the development of devices for the treatment of bradycardia, ventricular arrhythmia, and heart failure and for the prevention of sudden cardiac arrest leading to the delivery of pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) plus ICD (CRT-D) and to the recent subcutaneous implantable cardioverter-defibrillator (S-ICD) [23][24][25][26][27]. Infectious complications leading also to endocarditis [1,8,[28][29][30][31][32][33][34][35][36] and non-infectious complications [9,21,23,[37][38][39][40] often necessitating removal [1,2,8,[40][41][42][43][44][45][46] affect patients' wellbeing also leading to psychological difficulties increase [47][48][49][50][51][52][53] in the emerging scenario of concomitant problems and diseases and in patients also needing of device revision and upgrade. Moreover, the modern ICDs in the market deliver maximum energy of 35 to 41 J in relation to the model using single-coil leads or dual-coil leads.…”